Here are relevant reports on : non-opioid-pain-treatment-market
-
Medical Nitrous Oxide Market by Product (Gas, Liquid), Application (Anesthesia, Pain, Cryosurgery, Surgical Insufflation), End User (Hospital, Home healthcare, Academic, Research Institution), Key Stakeholder & Buying Criteria - Global Forecast to 2029
The global medical nitrous oxide market, valued at US$1.7 billion in 2022, stood at US$1.8 billion in 2023 and is projected to advance at a resilient CAGR of 6.6% from 2023 to 2029, culminating in a forecasted valuation of US$2.8 billion by the end of the period. The market is primarily driven by factors such as an increase in surgical procedures, a growing aging population, advancements in healthcare infrastructure, and growth in the dental industry.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Ultrasonic Tissue Ablation System Market by Type (HIFU Ablators, MRGFUS Ablators, Ultrasonic Surgical Ablation, Shock Wave Therapy Systems), Application (Cardiac Diseases, Cancer, Pain Management) & End User (Hospitals, Clinics) - Global Forecast to 2023
The global ultrasonic tissue ablation system market is expected to reach USD 1,449.2 million by 2023 from USD 840.9 million in 2018, growing at a CAGR of 11.5%. Increasing prevalence of chronic diseases; rising adoption of minimally invasive surgeries; ongoing technological advancements in the field of ablation devices, growing awareness about benefits of ablation procedures over conventional therapeutic and surgical procedures, and rising number of hospitals and surgical centers are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new devices, thus propelling the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Transdermal Patches Market by Type (Drug-in-adhesives, Matrix, Reservoir Membrane), Adhesive (Acrylic, Silicone, Hydrogel), Application (Pain, CVS, Hormonal), Distribution Channel (Pharmacy (Retail Online, Hospital)), End User & Region - Global Forecast to 2029
The global transdermal patches market, valued at US$5.9 billion in 2022, stood at US$6.2 billion in 2023 and is projected to advance at a resilient CAGR of 4.5% from 2023 to 2029, culminating in a forecasted valuation of US$8.0 billion by the end of the period. over the anticipated term, a number of problems, such as medication failure, transdermal drug delivery system recalls, and growing healthcare facility costs, will probably limit market growth to some degree.
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023
The transdermal drug delivery system market is projected to reach USD 7.1 billion by 2023, growing at a CAGR of 4.5%. The growth of this market is primarily driven by factors such as the increase in the prevalence of chronic diseases and technological advancements in transdermal drug delivery systems. The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
- Published: January 2019
- Price: $ 4950
- TOC Available:
-
Botulinum Toxins Market by Product (Botox, Dysport, Jeuveau, Myobloc), Application (Cosmetic (Wrinkle Removal, Contouring, Skin rejuvenation), Therapeutic (OAB, Migraine, Spasm, Pain)), Volume, End User (Clinics, Center), Region - Global Forecast to 2030
The global botulinum toxins market, valued at US$8.1 billion in 2024, stood at US$8.9 billion in 2025 and is projected to advance at a resilient CAGR of 11.7% from 2025 to 2030, culminating in a forecasted valuation of US$15.7 billion by the end of the period.The rising societal emphasis on maintaining a youthful appearance, especially within urban environments and professional contexts, is driving an increasing number of individuals to seek out cosmetic procedures, with botulinum toxins (commonly known as Botox) being among the most popular options.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Drug Device Combination Products Market by Type (Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application (Diabetes, Oncology, Pain, Opthamology), End User (Hospital, Home Care), and Region - Global Forecast to 2030
The global drug device combination products market, valued at US$224.70 billion in 2024, stood at US$243.02 billion in 2025 and is projected to advance at a resilient CAGR of 9.3% from 2025 to 2030, culminating in a forecasted valuation of US$379.17 billion by the end of the period. The increasing prevalence of chronic diseases worldwide, coupled with the introduction and approval of innovative advanced therapeutics, is driving significant market expansion.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Neurosurgery Devices Market by Product (Neuromodulation(Spinal Cord Stimulation, Deep Brain Stimulation) Neuroendoscopy), Application (Chronic Pain, Depression, Parkinsons, Ischemia, Transnasal Neuroendoscopy), Region - Global Forecast to 2024
The Neurosurgery Devices Market is expected to grow from USD 7.3 billion in 2019 to USD 13.5 billion by 2024, at a CAGR of 13.0% during the forecast period. Major players operating in the neurosurgery devices market include B. Braun Melsungen (Germany), Medtronic (US), Boston Scientific Corporation (US), Nevro Corporation (US), KARL STORZ (Germany), Abbott (US), Ackermann Instrumente (Germany), Hawk (China), Machida Endoscope (Japan), and adeor Medical (Germany).
- Published: September 2019
- Price: $ 4950
- TOC Available:
-
US Periodontal Disease Treatment Market by Product (Equipment, Consumables), Disease (Gingivitis, Periodontitis), Treatment (Bone Grafting, Scaling, Flap Surgery, Regeneration), End User (Clinics, Private DSOs) - Forecast to 2031
The US Periodontal Disease Treatment market, valued at USD 0.65 billion in 2025, stood at USD 0.68 billion in 2026 and is projected to advance at a resilient CAGR of 5.5% from 2026 to 2031, culminating in a forecasted valuation of USD 0.94 billion by the end of the period. Periodontal disease treatment in the US encompasses a wide range of technologies and solutions designed to support the diagnosis, treatment, and long-term management of gum-related conditions in dental practices.
- Published: January 2026
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
